P

Porton Pharma Solutions Ltd
SZSE:300363

Watchlist Manager
Porton Pharma Solutions Ltd
SZSE:300363
Watchlist
Price: 16.66 CNY 0.06%
Market Cap: 9.1B CNY
Have any thoughts about
Porton Pharma Solutions Ltd?
Write Note

Porton Pharma Solutions Ltd
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Porton Pharma Solutions Ltd
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
P
Porton Pharma Solutions Ltd
SZSE:300363
Inventory
ÂĄ780.7m
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
16%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Inventory
ÂĄ575.8m
CAGR 3-Years
24%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Inventory
ÂĄ4.5B
CAGR 3-Years
27%
CAGR 5-Years
19%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Inventory
ÂĄ2.3B
CAGR 3-Years
-1%
CAGR 5-Years
11%
CAGR 10-Years
16%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Inventory
ÂĄ6B
CAGR 3-Years
-11%
CAGR 5-Years
-13%
CAGR 10-Years
2%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Inventory
ÂĄ140.9m
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Porton Pharma Solutions Ltd
Glance View

Market Cap
9.1B CNY
Industry
Pharmaceuticals

Porton Pharma Solutions Ltd., rooted in the vibrant landscape of China's pharmaceutical sector, has strategically navigated its way to becoming a pivotal player in the global Contract Development and Manufacturing Organization (CDMO) industry. Founded in 2005, the company harnesses the intricate synergy between chemistry and biology to drive its core operations. Porton specializes in providing a comprehensive suite of services ranging from early drug development to commercial-scale manufacturing. The company's business model thrives on forming collaborative partnerships with global pharmaceutical and biotechnology firms, offering customized solutions tailored to specific drug production needs. By acting as an extension of its clients' research and development teams, Porton effectively reduces the time and investment required for its clients to bring new drugs to market, catalyzing its own revenue through long-standing service agreements. The essence of Porton’s value proposition lies in its robust technological capabilities and commitment to compliance with international quality standards, which ensures client trust and repeat business. Porton's facilities are outfitted with cutting-edge technologies that support complex chemical synthesis and advanced bioprocessing, allowing them to expertly handle high-potency and complex molecules. Additionally, the company leverages its strategic geographic advantage in China to offer competitive pricing while maintaining quality excellence, a crucial factor in contracting agreements. Through continuous investments in research and development, and a commitment to operational efficiency, Porton Pharma Solutions Ltd. not only accelerates its clients' drug development timelines but also enhances its own profitability, positioning itself as a leader in the evolving CDMO landscape.

Intrinsic Value
20.73 CNY
Undervaluation 20%
Intrinsic Value
Price
P

See Also

What is Porton Pharma Solutions Ltd's Inventory?
Inventory
780.7m CNY

Based on the financial report for Sep 30, 2024, Porton Pharma Solutions Ltd's Inventory amounts to 780.7m CNY.

What is Porton Pharma Solutions Ltd's Inventory growth rate?
Inventory CAGR 10Y
16%

Over the last year, the Inventory growth was 29%. The average annual Inventory growth rates for Porton Pharma Solutions Ltd have been 8% over the past three years , 16% over the past five years , and 16% over the past ten years .

Back to Top